Le Lézard
Classified in: Health
Subject: TRI

Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit


TEL AVIV, Israel and BETHESDA, Maryland, Jan. 27, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a series of tests conducted at the company's High Through-put Screening (HTS) facility in Israel, it has been shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumor properties, tested on human Gastrointestinal Cancer Cells.

Cannabinoid extract causing necrosis in Gastrointestinal cancer cell line. 
The Yellow color is a marker for necrosis. On the right - control, on the left ? after treatment with cannabinoids

CBC is an additional non-psychoactive cannabinoid and is one of the naturally occurring Phyto-cannabinoids. It bears a host of potential positive therapeutic qualities and may promote antimicrobial, anti?inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger Cannabis plants, albeit in small quantities. 

In these tests, the HTS platform was utilized to screen the necrotic effects of a variety of cannabinoids on human Gastrointestinal cancer cells, in addition to other cancer types previously tested. CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids, thus strengthening previously obtained results.

Dr. Yaakov Waksman, the company's head of cannabidiol research, said, "My working assumption is that these results show that a correlation may exist between a cannabinoid's Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumor activity, diminishing cancer cell's viability rates. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell's membrane, whereas their acidic form (CBCA and CBGA) - do not. This could explain the difference in anti-tumor activity rates demonstrated".

Dr. Eyal Ballan, CTO and Co-Founder, commented, "Gastrointestinal cancers are amongst the leading and most wide-spread causes of cancer-related deaths worldwide. We are intrigued by the results we have obtained in the lab, and our aim is to consider placing an emphasis on this organ system, and to further explore the differential anti-tumor properties of cannabinoids. We believe that these preliminary results vindicate our vision; which is to bring personalization into cannabinoid-based cancer treatments."

About Cannabics Pharmaceuticals

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.

For more information, please visit www.Cannabics.com.

For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter@Cannabics, Facebook@CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed January 14th, 2020. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.

For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1(877)-424-2429
[email protected]
http://www.Cannabics.com

 

Cannabics Pharmaceuticals Inc. Logo (PRNewsfoto/Cannabics Pharmaceuticals Inc.)

SOURCE Cannabics Pharmaceuticals Inc.


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: